Search Results
May 13, 2026, 06:50 ET Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
CARMIEL, Israel, May 13, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with
More news about: Protalix BioTherapeutics, Inc.
May 06, 2026, 06:50 ET Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
CARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with
More news about: Protalix BioTherapeutics, Inc.
Mar 18, 2026, 06:50 ET Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
CARMIEL, Israel, March 18, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with
More news about: Protalix BioTherapeutics, Inc.
Mar 11, 2026, 06:50 ET Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
CARMIEL, Israel, March 11, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with
More news about: Protalix BioTherapeutics, Inc.
Jan 05, 2026, 06:50 ET Protalix BioTherapeutics Letter to Stockholders
CARMIEL, Israel, Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with
More news about: Protalix BioTherapeutics, Inc.
Dec 17, 2025, 06:50 ET Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
and MARTINSRIED, Germany, Dec. 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with
More news about: Protalix BioTherapeutics, Inc.; Secarna Pharmaceuticals
Nov 13, 2025, 06:50 ET Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary
More news about: Protalix BioTherapeutics, Inc.
Nov 06, 2025, 06:50 ET Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
CARMIEL, Israel, Nov. 6, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary
More news about: Protalix BioTherapeutics, Inc.
Oct 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Oct 23, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Aug 14, 2025, 06:50 ET Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
Israel, Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary
More news about: Protalix BioTherapeutics, Inc.
Aug 07, 2025, 12:53 ET Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
Israel, Aug. 7, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary
More news about: Protalix BioTherapeutics, Inc.
Jul 21, 2025, 06:50 ET Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
Israel, July 21, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary
More news about: Protalix Biotherapeutics Inc.
Jun 30, 2025, 06:50 ET Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
Israel, June 30, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary
More news about: Protalix BioTherapeutics, Inc.
Jun 26, 2025, 08:30 ET STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer
several oncology therapeutics into clinical trials, including Plixorafenib (PLX-8394), a RAF (Rapidly Accelerated Fibrosarcoma) inhibitor for BRAF-mutant tumors; Exarafenib (KIN-2787), a next-gen RAF inhibitor; Bezuclastinib (PLX-9486), a KIT (CD117) inhibitor for KIT-driven cancers like GIST; and FGFR (Fibroblast
More news about: STORM Therapeutics